706820-95-3 Usage
Uses
Used in Organic Synthesis:
3-(tert-butylamino)sulfonyl-phenylboronic acid pinacol ester is used as a reagent in Suzuki-Miyaura cross-coupling reactions for the construction of carbon-carbon bonds in organic molecules. Its pinacol ester group enhances the stability and reactivity of the boronic acid, facilitating the formation of desired products in organic synthesis.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 3-(tert-butylamino)sulfonyl-phenylboronic acid pinacol ester is used as a building block for the development of pharmaceuticals and other biologically active compounds. Its unique functional groups and reactivity make it a valuable component in the synthesis of drug candidates with potential therapeutic applications.
Used in Research and Development:
3-(tert-butylamino)sulfonyl-phenylboronic acid pinacol ester is also used in research and development for exploring its potential applications in various fields. Its versatility and reactivity make it an interesting compound for studying new reactions and developing innovative synthetic methods.
Check Digit Verification of cas no
The CAS Registry Mumber 706820-95-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,6,8,2 and 0 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 706820-95:
(8*7)+(7*0)+(6*6)+(5*8)+(4*2)+(3*0)+(2*9)+(1*5)=163
163 % 10 = 3
So 706820-95-3 is a valid CAS Registry Number.
706820-95-3Relevant articles and documents
PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS
-
, (2011/02/24)
The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.
2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS
-
Page 76, (2008/06/13)
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.